Why investors search for Figure AI access
Figure AI has become the reference name in US humanoid robotics. Fortune described it as the most valuable US robotics company on August 19, 2026, when it compared Figure AI's reported 39 billion dollar valuation against Unitree's trading debut in Shanghai. That valuation traces back to Figure's own announcement, on September 16, 2025, that its Series C round exceeded 1 billion dollars in committed capital, led by Parkway Venture Capital with participation from Brookfield Asset Management, NVIDIA, Macquarie Capital, Intel Capital and other investors.
The scale of that round, paired with Figure's public work on its Helix AI system and BotQ manufacturing, keeps the name on watchlists even though there is no public stock to buy. Because Figure remains private, the 39 billion dollar figure is a reported valuation from a funding round, not a share price, and it is the main orientation point investors have to work with until any filing changes that.
What can block access
Figure's own rules are the biggest constraint on access. In a notice published July 8, 2026, the company stated that any transfer of its preferred or common stock, including upstream transfers of interests in special purpose vehicles or funds that hold Figure stock, requires board approval, and that any sale not explicitly approved by the board is void and will not be recognized on the company's books and records.
The same notice said that some online secondary marketplaces and sellers had attempted unauthorized transfers, and it warned that buying or selling Figure stock through unauthorized channels risks not being recognized as a stockholder, losing the investment, and legal exposure. Figure asks anyone verifying a proposed transaction to contact the company directly.
How Segmara helps
Segmara shows no standing secondary-market quote for Figure AI, because there is no indicative mark to show for this name. Segmara compiles the verified public record, including Figure's own funding announcements and its notice on transfer restrictions, so the entry reflects what the company itself has confirmed rather than secondhand chatter.
From there, Segmara lists the name for research only and does not sell, broker, or arrange share purchases. Any private transaction is subject to eligibility, availability, transfer approval, documentation, pricing and final terms, consistent with the board-approval requirement Figure has publicly stated applies to every transfer of its stock.